U.S. Overactive Bladder Market


USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

This research service covers the U.S. overactive bladder market from 2005-2015. Included is a disease overview, product analysis, total market revenue forecasts, product revenue forecasts, patient forecasts and market share analysis. The market is segmented by product: Detrol, Detrol LA, Ditropan, Ditropan XL, Enablex, Oxytrol, Sanctura, Sanctura XR, VESIcare, and others. Major market challenges, drivers, and restraints and identified and discussed as well as pipeline by phase.

Table of Contents

U.S. Overactive Bladder Market, Executive SummaryU.S. Overactive Bladder MarketIntroductionU.S. Overactive Bladder Market, Market IntroductionResearch Scope and MethodologyScope and SegmentationResearch MethodologyMarket OverviewMarket Engineering MeasurementsDisease OverviewTreatment OptionsPatient ForecastsIndustry ChallengesMarket DriversMarket RestraintsProduct AnalysisProduct AnalysisProduct ComparisonsRecently Approved ProductsPipeline AnalysisPhase IIIPhase IIPhase IU.S. Overactive Bladder Market, Competitive AnalysisOverviewCompetitive StructureForecasts and TrendsTotal MarketRevenue Forecasts by ProductMarket Share AnalysisCompany Market ShareProduct Market ShareDrug Delivery Market ShareU.S. Overactive Bladder Market, AppendixDecision Support DatabasesPopulation 65 PlusFemale Population 65 PlusMale Population 65 PlusTotal Life Expectancy at BirthBirth Rate

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.